衞信康(603676.SH):服務性收入主要來源於注射用多種維生素(12)、蔗糖鐵注射液等合作產品
格隆匯7月31日丨衞信康(603676.SH)近期在接待機構投資者調研時表示,服務性收入主要為向合作方收取的專利和技術使用費、商標/品牌使用費、市場管理和推廣服務費。“兩票制”實施後,由於部分合作生產的產品無法由本公司進行銷售,合作生產企業根據公司的訂單將生產的合作產品銷售併發貨至指定的藥品配送企業,公司主導全部的市場管理及推廣服務業務,公司向合作生產企業收取技術使用費、商標使用費、市場管理及推廣服務費,合成服務性收入。服務性收入主要來源於注射用多種維生素(12)、蔗糖鐵注射液等合作產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.